Ravulizumab - Alexion AstraZeneca Rare Disease
Alternative Names: ALXN 1210; ALXN 1810; ravulizumab-cwvz; UltomirisLatest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Alexion Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; AstraZeneca
- Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Registered Neuromyelitis optica
- Phase III Acute kidney injury; IgA nephropathy; Thrombotic microangiopathies
- Phase II Lupus nephritis
- Discontinued Acute lung injury; Amyotrophic lateral sclerosis; COVID-19 pneumonia; Dermatomyositis; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 01 Nov 2024 Alexion Pharmaceuticals completes the phase III CHAMPION-NMOSD trial in Neuromyelitis optica in USA, United Kingdom, Spain, Poland, South Korea, Japan, Italy, Germany, France, Denmark, Canada, Austria, Australia (IV) (NCT04201262)
- 30 Aug 2024 Alexion Pharmaceuticals plans a phase III trial for Paroxysmal nocturnal haemoglobinuria (Treatment naïve) in China (IV, Infusion) (NCT06578949)
- 13 Apr 2024 Updated efficacy data from a phase III CHAMPION MG trial in Myasthenia gravis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024).